Neurocrine Biosciences NBIX
NASDAQ NBIX
$174.41 +5.27 (+3.12%)
At close: Nov 11, 2026 · 4:00 PM EST

Neurocrine Biosciences (NBIX) Non-Current Deferred Tax Liability (2009 - 2026)

Updated

Neurocrine Biosciences' Non-Current Deferred Tax Liability came in at $105 million for Q3 2026, up 14.8% from the prior quarter.

Analysis

Neurocrine Biosciences (NBIX) Non-Current Deferred Tax Liability (2009 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Neurocrine Biosciences 17.13 Bn 13.21 Bn 1.10 Bn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2026 105.00 Mn
Jun 30, 2026 91.50 Mn
Dec 31, 2017 -500.00
Dec 31, 2009 500,000.00
API Access

Neurocrine Biosciences Non-Current Deferred Tax Liability API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deferred-tax-liability&ticker=NBIX&period=max&api_key=YOUR_API_KEY